Vision Ophthalmology Group announced that its founding member and Chief Executive Officer Andrew Geddes has decided to move into the position of Chairman of the Advisory Board after having successfully formed and grown Vision Ophthalmology Group since 2015. He will be succeeded as CEO by Roland Bruhin, previously CEO of Zuellig Asia Pacific, a family-owned multi-billion revenue speciality healthcare distribution business serving 300,000 healthcare professionals across 15 Asian markets.
Mr. Bruhin became the CEO Healthcare Distribution and Commercialization of Zuellig Asia Pacific in 2011 and has previously held various other positions during 15 years with the company. Before joining Zuellig Asia Pacific, he spent 5 years at Sika, the listed Swiss speciality chemicals company, and Wander, the food division of Sandoz / Novartis. Mr. Bruhin holds a Bachelor of Science in Chemical Engineering and a MBA from the London Business School.
"Vision Ophthalmology Group has rapidly become the leading provider of innovative solutions, products and services to ophthalmic surgeons in Europe," Mr. Geddes said in a news release. "I am excited to welcome Roland to our growing VOG family. He has developed an outstanding strategic and operational track record at Zuellig Asia Pacific which, like Vision Ophthalmology Group, has developed strong relationships with its suppliers and service- and quality-focused customers. Under Roland’s leadership, Zuellig Asia Pacific has shown strong organic growth, while delivering strong margins at the same time. Roland’s appointment is the result of a rigorous process conducted as part of our succession planning and we look forward to him leading our business through the next stage of its development. Vision Ophthalmology Group is a people business and the selection of the right person for every position is essential to its future success."
"I am delighted and proud to join Vision Ophthalmology Group. Its vision and strategy is exciting and unique and I look forward to building on its excellent foundations to drive the business through its next phase of development and continue to create value for all stakeholders. In particular, I look forward to working with Andrew and the exceptional team of Group C-level managers, the Group Vice Presidents, the Country Managers, and everyone associated within our subsidiaries and our valued customers and suppliers," Mr. Bruhin said.
Patric Klees, Vice Chairman of Vision Ophthalmology Group, commented: "Having had the vision and idea to form Vision Ophthalmology Group a long time ago, Andrew has been the driving force behind the business since its inception, doubling the size of the Group since 2015 and improving the margins of the business. On behalf of the Advisory Board, the management and all our colleagues I would like to extend to Andrew our greatest gratitude for his exceptional leadership and vision. In addition to building a strong, growing and unique business whose culture is testament to his character, he has also created a platform that delivers value to suppliers, customers and patients alike. Andrew will now become the Chairman of Vision Ophthalmology Group. He has experience in the ophthalmic space that is second to none in Europe and we are proud to continue to develop Vision Ophthalmology Group with his leadership."